Founded in 2011, ABL Lyon (formerly Platine Pharma Services) is a global leader in immunobiology, offering expert analytical services to advance innovative therapies from discovery to clinical testing. It was acquired in 2014 by ABL Inc., a global contract manufacturing and laboratory research service provider. ABL combines its expertise in translational science together with operational excellence to solve the challenging product development problems that are often faced by our clients as they bring their life-changing technologies to the world.
With cGMP facilities located in the U.S. and Europe, ABL is well positioned to provide comprehensive development and manufacturing support for protein and virus production utilizing single-use bioreactor platforms and other disposable technologies. ABL provides our clients with a fully integrated solution that includes cell line and process development, GMP manufacturing, QC release testing and QA/Regulatory support.
ABL’s contract research teams have decades of experience with immunoassays, developing custom assays and panels to support human clinical trials and preclinical animal studies. We routinely work with clients to design and run biomarker analyses to better understand the impact of cutting-edge therapies: the mechanism of action, correlates of protection, pharmacokinetic/pharmacodynamics studies and other critical safety and efficacy data.
ABL is a subsidiary of the Institut Mérieux, a global organization committed to serving medicine and public health across the globe.
Since 2011, ABL Lyon is accredited for the French research tax credit scheme (CIR).
ABL’s mission is to provide integrated product development services at the highest quality to advance client products from target discovery to clinical stage.